- Conditions
- Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
- Interventions
- Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Other Disorders of Bone Development and Growth
- Interventions
- Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 25 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Bone; Disorder, Development and Growth
- Interventions
- Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Hemostasis, Oral Contraceptive
- Interventions
- 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
- Drug
- Lead sponsor
- Teva Women's Health
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 21
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more